Double maintains 3 strategies that include BBIO - BridgeBio Pharma, Inc.
Yahoo
Acoramidis’s hazard ratio of .41 for time to ACM or first CVH versus placebo in the ATTRibute-CM study subgroup of ATTRv-CM patients achieved statistical significance in a pre-specified analysisThis profound treatment effect, due to the near-complete stabilization (≥90%) and binding of TTR, represents the greatest observed benefit to date for ATTRv-CM patients, an ATTR-CM population with poor prognosis In the ATTRibute-CM study, acoramidis demonstrated the most rapid benefit seen in any Phase 3
Yahoo
We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against the other best mid cap biotech stocks to buy. Is the Biotech Sector Oversaturated? On March 6, Jared Holz, Mizuho health care […]
Yahoo
In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated The approval was based on a Japanese Phase 3 study and the global ATTRibute-CM Phase 3 trial, which demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date. Key data from the ATTRibute-CM study include: In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related hospitalization (CVH)) durably separated relat
Finnhub
BridgeBio Pharma Inc: * BEYONTTRA , THE FIRST NEAR-COMPLETE TTRSTABILIZER, APPROVED IN JAPAN TO TREAT ATTR-CM * BRIDGEBIO PHARMA- WILL RECEIVE A $30 MILLION...
Yahoo
PALO ALTO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that cardiovascular outcomes data in patients with variant and wild-type ATTR-CM from the ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a flatboard poster presentation at the American College of Cardiology (ACC) Annual Scientific Sessions & Expo, taking place i
Yahoo
Alnylam stock jumped Friday after the drugmaker won a second Food and Drug Administration approval for its drug, Amvuttra.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PLG | -<0.01% | $124.31M | -14.79% | 0.00% |
BSM | 0.01% | $3.24B | -7.58% | 10.04% |
CQP | -0.05% | $32.91B | +35.41% | 5.06% |
OXY | -0.09% | $46.36B | -27.15% | 2.00% |
DTE | 0.11% | $28.64B | +25.16% | 3.02% |
HES | -0.14% | $49.33B | +2.46% | 1.30% |
XEL | 0.14% | $40.74B | +31.08% | 3.06% |
IMMP | -0.16% | $243.08M | -33.73% | 0.00% |
ALL | 0.20% | $54.44B | +18.46% | 1.83% |
HLN | 0.22% | $45.90B | +23.30% | 0.50% |
D | -0.26% | $47.91B | +15.63% | 4.73% |
PSQH | 0.27% | $93.55M | -56.05% | 0.00% |
SO | 0.29% | $100.14B | +28.63% | 3.09% |
MNR | 0.36% | $1.85B | -19.79% | 18.09% |
HMY | -0.36% | $9.41B | +76.02% | 0.89% |
GORV | -0.43% | $32.00M | -92.53% | 0.00% |
GSK | -0.44% | $76.56B | -9.39% | 4.02% |
WRB | -0.47% | $26.45B | +22.49% | 0.51% |
CVX | 0.48% | $291.28B | +3.76% | 4.19% |
EGO | 0.49% | $3.68B | +19.31% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BPMC | 40.87% | $5.75B | -2.41% | 0.00% |
CRSP | 36.86% | $2.93B | -47.07% | 0.00% |
HXL | 36.56% | $4.51B | -20.93% | 1.20% |
CYTK | 35.63% | $4.77B | -43.25% | 0.00% |
ROIV | 35.56% | $7.19B | -12.42% | 0.00% |
NTLA | 35.21% | $755.67M | -70.78% | 0.00% |
VSH | 34.65% | $2.16B | -28.21% | 2.94% |
CRS | 34.22% | $9.36B | +154.55% | 0.47% |
HHH | 34.19% | $3.77B | +13.02% | 0.00% |
SITE | 34.10% | $5.52B | -26.68% | 0.00% |
JOE | 34.10% | $2.75B | -18.03% | 1.20% |
OC | 34.08% | $12.59B | -13.92% | 1.91% |
W | 33.90% | $4.28B | -45.97% | 0.00% |
BLD | 33.88% | $9.15B | -29.15% | 0.00% |
DNLI | 33.61% | $2.00B | -29.07% | 0.00% |
LAB | 33.39% | $447.20M | -55.64% | 0.00% |
TILE | 33.36% | $1.19B | +20.19% | 0.21% |
IDYA | 33.35% | $1.43B | -61.21% | 0.00% |
IMNM | 33.16% | $583.44M | -68.94% | 0.00% |
RXRX | 32.96% | $2.13B | -40.76% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
LITB | -21.89% | $41.93M | -46.48% | 0.00% |
CBOE | -14.12% | $23.50B | +25.53% | 1.05% |
MO | -12.98% | $96.57B | +35.61% | 6.83% |
VZ | -12.55% | $188.34B | +4.44% | 5.84% |
STG | -10.69% | $28.76M | -44.31% | 0.00% |
TCTM | -10.31% | $3.92M | -82.22% | 0.00% |
ED | -10.06% | $38.69B | +21.90% | 2.95% |
T | -10.04% | $201.99B | +59.80% | 3.85% |
CME | -9.77% | $94.61B | +23.82% | 3.89% |
EC | -8.97% | $21.85B | -17.53% | 16.38% |
CMS | -8.80% | $22.33B | +25.86% | 2.76% |
KNOP | -8.38% | $260.66M | +43.40% | 1.46% |
BTCT | -8.04% | $20.15M | +14.57% | 0.00% |
PGR | -7.99% | $164.86B | +33.43% | 1.71% |
EA | -7.14% | $37.76B | +9.32% | 0.53% |
WTW | -7.07% | $33.64B | +25.30% | 1.06% |
FATBB | -6.97% | $56.94M | -23.78% | 14.95% |
SAVA | -6.76% | $67.15M | -93.25% | 0.00% |
TR | -6.71% | $2.24B | +3.83% | 1.15% |
GIS | -6.68% | $32.41B | -14.20% | 3.90% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 47.99% | $4.76B | 0.35% |
ARKG | 42.31% | $936.86M | 0.75% |
IBB | 42.12% | $5.61B | 0.45% |
IWO | 40.24% | $10.72B | 0.24% |
PBE | 40.08% | $224.98M | 0.58% |
VBK | 39.09% | $17.32B | 0.07% |
GNOM | 39.05% | $47.13M | 0.5% |
VTWO | 38.92% | $10.92B | 0.07% |
IWM | 38.54% | $62.65B | 0.19% |
XHE | 38.46% | $174.19M | 0.35% |
FBT | 38.43% | $1.08B | 0.56% |
QQQJ | 38.32% | $592.09M | 0.15% |
SCHA | 38.32% | $15.94B | 0.04% |
NUSC | 38.30% | $1.10B | 0.31% |
ISCG | 37.99% | $655.02M | 0.06% |
TMSL | 37.86% | $660.41M | 0.55% |
ESML | 37.65% | $1.76B | 0.17% |
VXF | 37.59% | $19.92B | 0.05% |
KOMP | 37.48% | $1.95B | 0.2% |
VB | 37.47% | $59.06B | 0.05% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -34.11% | $416.76M | 1.43% |
VIXY | -21.81% | $195.31M | 0.85% |
USDU | -16.12% | $206.96M | 0.5% |
UUP | -15.60% | $325.79M | 0.77% |
TAIL | -15.01% | $87.65M | 0.59% |
UGA | -11.93% | $87.23M | 0.97% |
TPMN | -11.76% | $33.32M | 0.65% |
OILK | -11.10% | $67.85M | 0.69% |
DBE | -10.89% | $55.52M | 0.77% |
USL | -10.76% | $47.77M | 0.85% |
USO | -10.74% | $972.70M | 0.6% |
BNO | -10.38% | $99.25M | 1% |
DBO | -10.23% | $202.41M | 0.77% |
USCI | -9.89% | $240.82M | 1.07% |
CTA | -9.23% | $978.30M | 0.76% |
GSG | -9.19% | $1.05B | 0.75% |
COMT | -8.38% | $684.20M | 0.48% |
FLTR | -6.94% | $2.41B | 0.14% |
DBC | -6.49% | $1.36B | 0.87% |
CCOR | -6.15% | $64.12M | 1.18% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
KMLM | 0.18% | $218.49M | 0.9% |
KCCA | 0.18% | $108.04M | 0.87% |
GLDM | 0.22% | $13.28B | 0.1% |
IYK | -0.25% | $1.53B | 0.4% |
FXY | 0.47% | $549.84M | 0.4% |
CLOI | 0.52% | $1.01B | 0.4% |
SHYD | 0.64% | $319.95M | 0.35% |
TBIL | 0.67% | $5.39B | 0.15% |
GCC | 0.94% | $149.77M | 0.55% |
BCD | -1.02% | $250.79M | 0.3% |
PWZ | 1.29% | $703.30M | 0.28% |
CGSM | 1.41% | $640.07M | 0.25% |
CMDY | -1.42% | $313.96M | 0.28% |
XLP | 1.45% | $16.87B | 0.09% |
EQLS | -1.53% | $4.80M | 1% |
BAR | 1.74% | $1.05B | 0.1749% |
ICLO | 1.76% | $354.74M | 0.2% |
AAAU | 1.77% | $1.32B | 0.18% |
FLMI | 1.89% | $613.41M | 0.3% |
MUST | 1.90% | $406.02M | 0.23% |
Current Value
$33.301 Year Return
Current Value
$33.301 Year Return